Overview Snapshot A 40-year-old woman presents to her physician’s office for management of her newly diagnosed rheumatoid arthritis. She reports that she has not tried any long-term medication for this disease and seeks advice. She is counseled on the immunosuppressive effects of this class of medications and is tested for latent tuberculosis prior to starting therapy. Introduction Tumor necrosis factor (TNF)-α inhibitors categories fusion proteins monoclonal antibodies Mechanism of action inhibits physiologic response to TNFα, an important component of inflammation Toxicity immunosuppression ↑ risk of infections ↑ risk of lymphomas reactivation of latent tuberculosis TNF-α plays a key role in granuloma formation and stabilization must always test for tuberculosis prior to starting TNF-α inhibitors Fusion Proteins Medications etanercept Mechanism of action fusion protein of the receptor for TNFα and immunoglobulin (Ig) G1 Fc produced by recombinant DNA acts as a decoy TNFα receptor Clinical use ankylosing spondylitis psoriasis rheumatoid arthritis Toxicity immunosuppression lupus-like syndrome Monoclonal Antibodies Medications infliximab adalimumab certolizumab golimumab Mechanism of action anti-TNFα monoclonal antibody Clinical use ankylosing spondylitis hidradenitis suppurativa inflammatory bowel disease psoriasis rheumatoid arthritis Toxicity immunosuppression gastrointestinal irritation